Screening for Pancreatic Cancer in Patients with an Inherited BRCA1, BRCA2, PALB2 or ATM Mutation
Clinicaltrials.gov identifier:
NCT02478892
Prevention
Study Contact Information:
Principal investigator:
Bryson Katona, MD
Phone: 855-216-0098
Email
Preliminary Evaluation of Screening for Pancreatic Cancer in Patients with an Inherited Genetic Risk Due to a BRCA1, BRCA2, PALB2 or ATM Mutation
About this Study
Improved screening for pancreatic cancer in high-risk groups, such as people with an inherited , , , or mutation, may help find cancer early and improve survival rates. People enrolled in this study will undergo screening using endoscopic or of the abdomen.
What the Study Entails
People enrolled with the study will have annual screening for pancreatic cancer using one of two procedures:
- Endoscopic (EUS) involves passing a tiny scope with an attached probe down the esophagus to the stomach. This allows doctors to look closely at the pancreas. EUS is performed as an outpatient procedure under anesthesia.
- Magnetic resonance imaging () is a type of imaging that uses magnetic fields to look closely at internal organs such as the pancreas.
Participants will be screened and followed for ten years.
Note: EUSs and MRIs performed on study participants are billed to insurance, and the study does not cover the cost of these procedures.
Study Site
Pennsylvania
- Philadelphia: Abramson Cancer Center of the University of Pennsylvania
Contact: Bryson Katona, MD by phone 855-216-0098 or email
Men and women, age 18 years or older, are eligible if they have:
- Inherited , , , or mutation
- If no history of pancreatic ductal () in a first or second degree relative, then age of study participant must be >= 50 years old
- If there is a history of in a first or second degree relative, minimum age to participate in study is 10 years younger than the age of onset of the youngest relative with pancreatic cancer
- People who are pregnant